Group items matching

in title, tags, annotations or url

A new study has revealed that the risk of death from COVID-19 decreases significantly after vaccination, but this protection diminishes after six months, providing evidence for continued booster doses. Researchers from the UK Health Security Agency (UKHSA), who analysed more than 10 million cases of COVID-19 in adults in England between May 2020 and February 2022, found a clear association between vaccination and reduced mortality. But they also highlighted a crucial timeframe - within six months of the last vaccine dose - when Case Fatality Risk (CFR) - the proportion of cases that resulted in death - was consistently at its lowest across all age groups. After this, the protective benefit of the vaccine began to wane and CFR increased.

Even as the UK agrees deals for 14 million additional vaccine doses from Moderna and Pfizer, the Royal Pharmaceutical Society has renewed its calls for community pharmacies in England to play an increased role in delivering booster jabs for Covid-19. "Pharmacists and pharmacy teams across the health service in England have been crucial to the success of the flu and Covids-19 vaccination programmes from the outset," said Thorrun Govind, chair of the RPS in England, who has been making a case on national television for an increased role of the profession. She added: "They continue to go above and beyond to support patient care, engaging with local communities and helping to overcome vaccine hesitancy. "They've already done so much this year to look after patients in really difficult circumstances, but many will be ready to rise to the challenge of this new national effort."

Pharmacy teams are being encouraged to support the ground-breaking Platform Adaptive trial of Novel antivirals for early treatment of Covid-19 In the Community (PANORAMIC) study by raising awareness among patients. The study aims to find out whether new antiviral treatments can help Covid-19 patients avoid hospital admission and support a quicker recovery. The PANORAMIC trial will allow researchers to gather data on the potential benefits of treatments to patients and will help the NHS to develop plans for rolling out the products to further patients in 2022. Anyone over the age of 50 or between 18 to 49 with certain underlying health conditions can participate in the trial after receiving a positive PCR or lateral flow test result for Covid-19. People who wish to participate in the trial can sign up themselves through the study's website and may be contacted by a member of the clinical team in a general practice that has been set up to deliver the PANORAMIC trial.

Global demand for Pfizer's oral Covid-19 antiviral treatment Paxlovid has been unexpectedly low due to complicated eligibility requirements, reduced testing, and potential for drug interactions, according to a media report. Demand also has been hampered by the perception that Omicron infections are not that severe. Paxlovid was expected to be a major tool in the fight against Covid after it reduced hospitalizations or deaths in high-risk patients by around 90 per cent in a clinical trial. Thousands of people still die from Covid-19 every week, even as global infections are far off their peak. And there are only a few proven antiviral treatments, of which Paxlovid is the most attractive. The others are Merck & Co's far less effective rival pill molnupiravir, and Gilead Sciences' intravenous remdesivir.

70 per cent of community pharmacies still waiting for government nod to start Covid booster jabdesc-Nearly 70 per cent of community pharmacies in England that offered to participate in the Covid-19 booster programme are still waiting for approval or have been refused, ministers admitted on Monday (December 13). The Liberal Democrats' health spokesperson, Daisy Cooper, exposed the low approval rate and long delays through a written parliamentary question to the health secretary as to "how many community pharmacies were providing Covid-19 vaccinations as of 3 December 2021."In response vaccines minister Maggie Throup said: "As of the end of September 2021, 4,733 contractors submitted 5,376 expressions of interest to take part in the booster vaccination programme, with 1,454 accepted."She added: "As of 3 December 2021, 1,336 community pharmacy vaccination sites were actively providing the service." Some applications were decided by NHS England rather than the Department of Health and Social Care (DHSC).

Britain has become the first country to approve a Codiv-19 vaccine that targets both the original and Omicron variant of the virus. Medicines regulator MHRA approved the so-called bivalent vaccine made by US drug company Moderna as a booster for adults. The agency's decision was based on clinical trial data that showed the booster triggered "a strong immune response" against both Omicron (BA.1) and the original 2020 virus, it said. The MHRA also cited an exploratory analysis in which the shot was also found to generate a good immune response against the currently dominant Omicron offshoots BA.4 and BA.5. "The first generation of Covid-19 vaccines being used in the UK continue to provide important protection against the disease and save lives," MHRA chief executive June Raine said in a statement. "What this bivalent vaccine gives us is a sharpened tool in our armoury to help protect us against this disease as the virus continues to evolve."

UK regulator has approved a new age-appropriate formulation of the Pfizer BioNTech Covid-19 vaccine for use in children aged 5 to 11 years old. The new paediatric formulation of Covid vaccine meets the required safety, quality and effectiveness standards, the Medicines and Healthcare products Regulatory Agency (MHRA) announced on Wednesday (December 22). Dr June Raine, MHRA chief executive said that parents and carers can be reassured that this approval has been given after robust review of safety data. These data showed a favourable safety profile for use in 5-11-year olds compared with that seen in other age groups, the regulator said. Raine said: "We have carefully considered all the available data and reached the decision that there is robust evidence to support a positive benefit risk for children in this age group.

The Royal Pharmaceutical Society (RPS) has cautioned that measures to protect people against Covid-19 must be stepped up in the wake of discovery of the new variant, B.1.1.529. It has urged members of the public to practice 'hands, face, space and ventilation' protection measures which have become less used in the last few months. RPS director of pharmacy Robbie Turner said that though it was too early to conclude about the transmissibility or resistance of the new variant to current vaccines, quick action should be taken to protect the public. "Each one of us must take the necessary precautions of wearing a mask in higher risk situations, maintaining social distancing wherever possible, ensuring there's appropriate ventilation indoors when meeting others and washing our hands regularly." Encouraging people to take Covid vaccine, he said, it "is still our best defence against this virus".

Britain called on Sunday (November 21) for international action on the issue of medical devices such as oximeters that work better on people with lighter skin, saying the disparities may have cost lives of ethnic minority patients during the Covid-19 pandemic. Health secretary Sajid Javid said he had commissioned a review of the issue after learning that oximeters, which measure blood oxygen levels and are key to assessing Covid patients, give less accurate readings for patients with darker skin. "This is systemic across the world. This is about a racial bias in some medical instruments. It's unintentional but it exists and oximeters are a really good example of that," Javid said during an interview with the BBC. Asked whether people may have died of Covid-19 as a result of the flaw, Javid said: "I think possibly yes. I don't have the full facts." He said the reason for the discrepancies was that a lot of medical devices, drugs, procedures and textbooks were put together in white majority countries.

Labour Party leader Keir Starmer leader has tested positive for Covid-19 for a second time, a spokesperson confirmed on Wednesday (January 5). Starmer had been due to face prime minister Boris Johnson at a question and answer session in parliament later today. His deputy, Angela Rayner, will take his place, the spokesperson added. Starmer had tested positive for Covid-19 last October and self-isolated four times after coming into contact with other positive cases on several occasions.

The Pharmacists' Defence Association has reported an increase in the number of pharmacists calling its advice line to inform about the incidences of violence and intimidation from protesters opposing the Covid-19 vaccination programme. The association noted that such incidents have become more common with protesters "gaining entry to premises in groups and trying to disrupt Covid-19 vaccinations from taking place." In many cases, pharmacists, staff, and members of the public have been subjected to verbal threats, causing distress and anxiety among those working to deliver the vaccination programme in a safe environment. The PDA reminded that employers, having a contract with the NHS for the Covid-19 vaccinations, have a duty to keep their staff safe whilst at work. The General Pharmaceutical Council (GPhC) standards for pharmacy premises also carry a duty to ensure the safety of staff and the public receiving services on those premises.

A pair of pharmacist brothers, who also own a popular restaurant in Kent, have started an innovative initiative 'Jabs with Kebabs' to encourage their community in England to come forward and take their Covid-19 vaccines. Rav and Raj Chopra, who own V's Punjabi Grill, an Indian restaurant in Gravesend, established the walk-in vaccine site after their father, Jagtar Chopra, became unwell with Covid-19 last year. The duo is among thousands to volunteer for the National Health Service (NHS) vaccine programme. Talking to the PA news agency, Raj said he was inspired by the experience of his father, who got infected with the virus and has fully recovered since then. "From a personal point of view, it was very debilitating to see Dad like that," said Raj Chopra. "It got everyone's emotions in play.

Alliance Healthcare UK has won a 'special achievement' award for its work during the Covid-19 pandemic at the Logistics UK Awards 2021. The pharmaceutical wholesaler and it's subsidiary, Alloga UK - a specialist provider of supply chain solutions for healthcare manufacturers - received the 'Special Recognition Award for Outstanding Response to Covid' at an event held in central London on Thursday, December 9, 2021 - beating off stiff competition from a number of high profile challengers. Alliance Healthcare's new managing director Marie Evans said: "I am delighted that our business and team of 6,000 colleagues have been recognised at this level for our contribution to the fight against Covid-19. Our main aim over this unprecedented period is to support the NHS, pharmacy and all UK patients, and this award is true recognition for all of that hard work and dedication." The special award category was open to an individual or organization that demonstrated an outstanding response to the pandemic in 2020 within the logistics sector and included seven other nominees including the likes of National Highways, Hermes UK and Yodel.

Deviating from the initial schedule to kick off the flu and Covid-19 vaccination campaigns in October, the NHS England has announced that the autumn vaccination drive will commence sooner than expected in England, starting on September 11. This decision was taken as a precaution in response to a new Covid-19 variant. The precautionary measure is being taken as the Department of Health and Social Care and the UK Health Security Agency examined the variant BA.2.86, which was first detected in the UK on Friday, August 18, 2023, the NHSE said on Aug. 30. While NHS England had previously announced that vaccinations for both NHS programmes would begin on October 2 for residents of older adult care homes, appointments for other eligible groups were scheduled for the following week, starting on October 7. This decision prompted community pharmacy leaders to denounce the delayed start of the flu service as 'unacceptable'.

People who test positive for Covid-19 on rapid lateral flow tests will not need to confirm their results with a follow-up PCR test if they are not showing symptoms, the UK Health Security Agency said on Wednesday (January 5). Britain is reporting record daily case numbers, and the UKHSA said that the high prevalence meant the chance of a false positive from a lateral flow device (LFD) was low. The move could also reduce the burden on the testing system, and reduce confusion if the test results contradict each other. At current levels of prevalence, officials say a positive LFD result is likely to be accurate, even if a follow-up PCR were negative. "While cases of Covid continue to rise, this tried-and-tested approach means that LFDs can be used confidently to indicate Covid-19 infection without the need for PCR confirmation," said UKHSA chief executive Dr Jenny Harries.

More than 7,000 hospitalisations and deaths in the UK could have been averted in summer 2022 if people had received their recommended COVID-19 vaccine doses, a new study published in The Lancet has revealed. The largest ever study carried out in the UK found that between a third and a half of the UK population had not had the recommended number of COVID vaccinations and boosters by summer 2022. In Northern Ireland, nearly 50 per cent of the population were under-vaccinated, while the proportion of under-vaccinated people in England was 45.7 per cent, 34.2 per cent for Scotland and 32.8 per cent Wales. Researchers from the Health Data Research UK (HDR UK) and the University of Edinburgh analysed the electronic health records of 67 million residents aged 5 and older from across the four countries during June 1 to September 30 2022.

French drugmaker Sanofi said on Monday (June 13) an upgraded version of the Covid-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus's main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot. While the two companies' first experimental Covid shot is undergoing review by the European Medicines Agency, Sanofi and GSK have continued work on a vaccine that is moulded on the now-supplanted Beta variant, hoping still that it will confer broad protection against future viral mutations. Sanofi said this new vaccine candidate was shown to significantly boost antibody levels against a number of variants of concern, when given to trial participants who had an initial course of mRNA vaccines, a type made by BioNTech-Pfizer and Moderna. In a separate trial conducted by a French hospitals network, Sanofi's Beta-adapted booster shot triggered a higher immune response than Sanofi's first-generation shot or Pfizer-BioNTech's established vaccine in previously vaccinated volunteers.

Once the initial fear and anxiety around the COVID-19 pandemic passed, a new normal in the healthcare workforce world emerged. By now you've likely returned to work in some capacity. Maybe you now work remotely (Work from Home, or the new shorthand, WFH) and will do so for a while. Maybe you've recently returned to work under social distancing and protective face cover/mask constraints. Either way, the effects of COVID-19 loom for the long haul. Sit back, adjust your face mask, and learn how to adapt and thrive in the new world of healthcare workforce and provider recruitment.

The NHS Covid-19 vaccination programme has administered more than 40 million second doses following a bumper week that saw over 200,000 people coming forward for their second jab. Last week, more than 65,000 people aged 18 and over also stepped up to get their first dose of the Covid-19 jab. The NHS continued to encourage people to come forward for their first, second or third doses. Recent data from the UK Health Security Agency (UKHSA) showed that two doses of the vaccine are not enough to avoid the Omicron infection, but a booster significantly increases protection against the variant. Since the start of vaccination programme, NHS England has administered more than 113 million jabs in total. However, more than 1.1 million people aged 18 and over have still not come forward for their second dose.

As part of efforts to streamline spending and enhance resource allocation within the healthcare system, the NHS has chosen to cease providing the free vaccinations for all, which were initially introduced in 2020. Approximately 12 million British citizens will not have access to free flu vaccinations and Covid-19 boosters during the upcoming winter, according to NHS. Furthermore, the NHS plans to defer flu vaccine distribution to October, aiming to heighten protection for those aged 65 and older and other eligible groups in the high-risk winter months. However, this has stirred panic among pharmacies, given their advanced planning based on the initial start date of September 1 for vaccinations. On Tuesday (Aug. 8), the Joint Committee on Vaccination and Immunisation (JCVI) released NHS guidelines indicating that Covid-19 booster shots, starting from autumn, will not be provided to individuals aged 50 to 64 who are in otherwise good health. Similar guidance had already been released for flu, rendering 12 million middle-aged Britons ineligible for free jabs, JCVI said. Prior to the pandemic, influenza vaccinations were available to healthy adults aged over 65, alongside children and younger adults with medical conditions. Amidst the pandemic, the distribution of flu vaccinations was expanded to include individuals aged 50 to 64, in alignment with the criteria for Covid-19 boosters.